Swedish Orphan, Under Pressure At Home, Looks to Commerical Swap With China Company For Growth
This article was originally published in The Pink Sheet Daily
Executive Summary
The Nordic specialist, facing commercial difficulties at home and the loss of co-promotion deals for a handful of drugs, lines up the first product to be included in a pan-European product rights deal with Chinese partner Dongbao.
You may also be interested in...
PET Drugs May Get Shorter Path To FDA Approval
For positron emission tomography drugs with low levels of use that are needed to diagnose rare conditions, an expanded access IND may be the best regulatory pathway.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.